Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Buprenorphine, a mu-opioid partial agonist, has demonstrated efficacy for the treatment of opioid dependence comparable to that of methadone. The clinical utility of buprenorphine would be enhanced if it could be dosed on a less than daily basis. The current study is a parallel-group outpatient clinical trial of daily versus alternate-day dosing with 8 mg sublingual (s.l.) buprenorphine. Participants were randomly assigned to daily (n = 51) or alternate-day (n = 48) schedules of active medication administration for an 11-week double-blind trial. Patients assigned to alternate-day buprenorphine received placebo every other day. Primary outcome measures were retention in treatment and urine specimens positive for opiates. Clinic attendance, dose adequacy ratings, withdrawal symptomatology, and urine specimens positive for cocaine were secondary outcome measures. Neither endpoint analysis with the intent-to-treat sample nor time course analysis with treatment completers revealed any statistically significant differences between the dosing schedules on any outcome measure. Examination of 95% confidence intervals suggested a non-significant trend for the daily dosing schedule to have superior clinical efficacy at the dose tested. Nevertheless, these results are generally consistent with previous studies of less than daily dosing with buprenorphine and support the conclusion that an alternate-day dosing schedule can be effective in and acceptable to a substantial portion of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 2×
“Buprenorphine displays the advantages of a pure mu-opioid agonist; its subjective effects are agonist-like (e.g., Jasinski et al., 1978; Pickworth et al., 1993), it blocks the effects of concurrently administered opioids (e.g., Jasinski et al., 1978; Bickel et al., 1988; Rosen et al., 1994), and it…”
BackgroundClinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773 · cited 3×
“Two recent studies of acute buprenorphine administration (Walsh et al., 1994; Walsh et al., 1995) suggest that the agonist effects of buprenorphine reach a ceiling at the 8-16-mg dose range.”
BackgroundSelf-citationBuprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298 · cited 1×
“Buprenorphine also suppresses heroin use (Mello and Mendelson, 1980; Mello et al., 1982), and is safer than pure mu-agonists like methadone and LAAM.”
BackgroundAcute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283
Self-citation
Cited by
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Self-citationConnock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., et al. (2007) · Health Technology Assessment · doi:10.3310/hta11090 · Cited by 585
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
“Although previous studies have indicated a potentially useful efficacy of buprenorphine for heroin dependence, 8–15 , 23 the placebo-controlled”
Background
Metadata
- Authors
- Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 1995-11
- Volume
- 40
- Issue
- 1
- Pages
- 27-35
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2113517664
- Cited by
- 87
- References
- 4
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. https://app.cochat.ai/papers/10.1016/0376-8716(95)01189-7
- The paper
- Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995). Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug and Alcohol Dependence. https://doi.org/10.1016/0376-8716(95)01189-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.